

REMARKS

Claims

Claims 74–84 are pending of which claims 1–73 were previously cancelled without prejudice or disclaimer.

Amendments

The claims have been amended to correct recite sequence identifier numbers. Support for the amendment can be found in the enclosed sequence listing and the entirety of the disclosure contained in Applicants' originally-filed specification.

The specification has been amended to recite sequence identifier numbers of the various biological sequences that appear in the tables and the figures. An obvious typographical error in the numbering of the amino acid residues in FRL1–4 (SEQ ID NO: 152) has been fixed. Namely, position “22” was corrected to position “24” in Table 2 of the specification. Since the length of the proximal FRL1 sequence is 23 amino acids, it is clear to one of ordinary skill in the art that the CDRL1 sequence of SEQ ID NO: 6, 7, 8 or variant thereof, which follows FRL1, has to start at amino acid 24 of the FRL1–4 polypeptide chain.

It is respectfully submitted that the amendments do not recite new matter nor do they narrow the scope of the claims. Entry thereof is respectfully requested.

Sequence listing

A revised sequence listing, both in print and electronic format are enclosed herewith for the Examiner's review. Entry thereof is earnestly solicited.

The Commissioner is hereby authorized to charge any fees associated with this response to Deposit Account No. 13-3402.

Respectfully submitted,

/Sagun KC/

Sagun KC, Reg. No. L0510
Agent for Applicant(s)

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: DORRIE-0019

Date: November 24, 2008